by adoptive transfer is limited by the need for their expansion in vitro and limited purity. Recently, an interleukin (IL)-2/anti-IL-2 neutralizing monoclonal antibody (IL-2/anti-IL-2 mAb) complex has been shown to expand these Tregs. We examined the capacity of a modified IL-2/anti-IL-2 mAb treatment to expand Tregs and inhibit both the progression and development of developed atherosclerosis. Methods and Results-Six-week old apolipoprotein E-deficient mice fed a high-fat diet for 8 weeks were administered IL-2/anti-IL-2 mAb commencing 2 weeks after starting the diet. Tregs in the spleen, lymph node, and liver were selectively expanded without affecting CD4ϩ, CD8ϩ, or natural killer cells. Tregs were increased in lesions and lesion size reduced. CD4ϩ T-cells, macrophages, mature dendritic cells, proliferating cell nuclear antigenϩ cells, and monocyte chemoattractant protein-1 and vascular cell adhesion molecule-1 were reduced. In anti-CD3-stimulated splenocytes, proliferation and secretion of Th1, Th2, and Th17 (IL-17) cytokines and IL-1␤ were reduced. To determine whether treatment attenuated progression of developed atherosclerosis, 6-week-old apolipoprotein E-deficient mice were fed a high-fat diet for 6 weeks, followed by IL-2/anti-IL-2 mAb treatment for 6 weeks while continuing the high-fat diet. Treatment also increased Tregs without affecting CD4ϩ, CD8ϩ, or natural killer cells, suppressed inflammation, and greatly attenuated progression of atherosclerosis.
A therosclerosis is a multifactorial vascular disease involving interactions between cholesterol-rich lipoproteins, endothelial and smooth muscle cells, macrophages, dendritic cells, and lymphocytes. 1 It leads to severe clinical events caused by plaque rupture and thrombotic occlusion of arteries and is the main cause of acute coronary syndrome and stroke. Studies of atherosclerotic lesions indicate that CD4ϩ lymphocytes are present in human and mouse lesions early in the development of disease, 2,3 and adoptive transfer of these cells is proatherogenic. 4 CD4ϩ T cells produce a variety of cytokines including interferon-␥, tumor necrosis factor-␣, interleukin (IL)-1, and IL-10, which can influence the development and characteristics of atherosclerotic plaques.
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More recently, other CD4ϩ T cell subtypes have been identified in lesions, including Th17 cells 5 
and CD4ϩCD25ϩ
Foxp3ϩ regulatory T cells (Tregs). 6 Deletion of Tregs accelerates development of atherosclerosis, 7 and their adoptive transfer suppresses atherosclerosis. 7 Although the mechanisms by which they suppress atherosclerosis are yet to be defined, these cells produce a number of immunosuppressive Figure 1 . Expansion of CD4ϩCD25ϩFoxp3ϩ Tregs in lymphoid organs after IL-2/anti-IL-2 mAb treatment and dose-dependent suppression of CD4ϩ T cells. A, Representative results from individual mice of CD25 and Foxp3 expression in spleen, liver, and inguinal lymph nodes assessed by flow cytometry, 7 and 14 days after commencing treatment with IL-2/JES6 -1 mAb complexes or vehicle showing expansion of Tregs; for day 7, mice were treated with complex or vehicle from day 1 to day 5 and examined on day 7, whereas for day 14, mice were treated from day 1 to 5 and then days 10 to 12 and examined on day 14. FACS plots represent the percentage of CD25ϩ and Foxp3ϩ cells within the CD4ϩ population. B, CD4ϩCD25ϩFoxp3ϩ cells within the CD4ϩ population in spleen, Dinh et al IL-2/Anti-IL-2 mAb and Atherosclerosis molecules, including transforming growth factor (TGF)-␤, 8 and IL-10. 9 In vitro, Tregs inhibit the proinflammatory effects of macrophages by steering macrophage differentiation toward an anti-inflammatory phenotype and reducing lipid accumulation. 10 Because of their ability to attenuate atherosclerosis, it has been suggested that Tregs may be suitable for treating atherosclerosis. 11 Adoptive transfer of naturally occurring Tregs as well as antigen-specific Tregs attenuate development of atherosclerosis. 12 Also, immunization with an apolipoprotein B-100 fusion protein has been associated with increases in antigen-specific regulatory T cells and reductions in atherosclerosis. 13 Despite such studies, therapy using adoptive transfer is limited by the lack of sufficient purity of Treg preparations and the requirement to expand these cells in vitro in sufficient numbers for transfer. 11 Other immunologic approaches to attenuate the immunoinflammatory component of atherosclerosis are also limited in their efficacy to suppress atherosclerosis, particularly already developed atherosclerosis. For example, anti-CD3 treatment of mice induces CD4ϩLAPϩ Tregs and attenuates development of atherosclerosis but not progression of already developed atherosclerosis. 14 Other approaches, including inducing tolerance to antigens such as oxidized low-density lipoprotein, also appear restricted to preventing development rather than progression of developed disease. 15 Given these limitations, an alternative approach to suppress the immunoinflammatory component of atherosclerosis might be to expand Tregs in vivo using specific cytokine therapy.
IL-2 is a cytokine mainly produced by activated T cells and is a potent growth factor for immune cells, including T cells and natural killer (NK) cells. 16 IL-2 has 2 major clinical uses: as antitumor therapy for renal carcinoma and melanoma and for treating HIV disease. 16 The magnitude and duration of effects of such cytokines can be markedly improved by complexing with antibodies, 17 and more recently selective targeting of immune cells has also been achieved. By injecting low doses of IL-2 complexed with the anti-IL-2 neutralizing monoclonal antibody (mAb) JES6 -1, Webster 18 recently reported selective expansion of Tregs. The increase in Tregs is specific to this IL-2/anti-IL-2 mAb complex as complexing IL-2 with other anti-IL-2 neutralizing antibody clones (eg, S4B6) drives expansion of CD8ϩ T cells and NK cells. 19 Short-term treatment with IL-2/anti-IL-2 mAb (JES6 -1) complex increases Tregs up to 6-fold. 18 Here we investigated whether treatment with IL-2/anti-IL-2 mAb (JES6 -1) complex inhibits atherosclerosis development and progression of developed atherosclerosis in apolipoprotein E-deficient (ApoE Ϫ/Ϫ ) mice. We modified earlier short-term treatment protocols making the treatment suitable for inducing long-term elevations in Tregs. We demonstrate that IL-2/anti-IL-2 mAb (JES6 -1) complex therapy induces sustained increases in Tregs, attenuates immunoinflammatory processes that promote atherosclerosis, thereby inhibiting progression of already developed atherosclerosis as well as development of atherosclerosis.
Methods

Animals and Experimental Protocol
Six-week-old male ApoE Ϫ/Ϫ mice were commenced on a high-fat diet, then 2 weeks later they were administered a recombinant mouse (rm) IL-2/anti-IL-2 mAb (JES6 -1) complex (1 g rmIL-2 plus 5 g anti-IL-2 mAb). During the first week of treatment the mice received 5 consecutive daily doses i.p., after which they received 3 doses weekly for the duration of the study. Control mice received PBS or 5 g anti-IL-2 mAb. Mice were euthanized at 14 weeks of age and atherosclerotic lesions assessed. To evaluate the effects of rmIL-2/ anti-IL-2 mAb complex treatment on progression of atherosclerosis, 6-week-old ApoE Ϫ/Ϫ mice were fed a high-fat diet for 6 weeks, then the mice were treated with the cytokine-antibody complex as above for 6 weeks while continuing the high-fat diet.
An expanded Materials and Methods section is available in the online-only Data Supplement.
Statistical Analyses
Results are expressed as meanϮSEM. Comparisons between groups were carried out using Student t test or Mann-Whitney U test, depending on whether the data were normally distributed, as assessed by using the Kolmogorov-Smirnov test. For multiple comparisons, results were analyzed using 2-way (2-factor) ANOVA (after confirming normality of distribution using the Kolmogorov-Smirnov test), followed by Bonferroni post test. A value of PϽ0.05 was considered as statistically significant.
Results
Characteristics of CD4؉CD25؉Foxp3؉ Regulatory Cells Expanded In Vivo by IL-2/Anti-IL-2 mAb Complex Treatment
Previous studies on Treg expansion after IL-2/anti-IL-2 mAb (JES6 -1) complex injection have been limited to 3 days. 18 Consequently, we designed a dosage regimen that could be used for stimulating prolonged increases in Tregs numbers during development of atherosclerosis. We administered a total dose of 6 g (5 g anti-IL-2 mAb [JES6 -1] plus 1 g mrIL-2) per i.p. injection on 5 consecutive days, measured Tregs on day 7, then administered the IL-2/anti-IL-2 mAb complex on days 9 to 11 and again measured Tregs on day 14. Tregs within the CD4ϩ T cell population increased markedly in spleen, liver, and inguinal lymph nodes after 5 days of treatment, 4-fold in the spleen (Pϭ0.0032) and liver (Pϭ0.0394) and 3-fold in the inguinal lymph nodes (Pϭ0.0129; Figure 1A and 1B); total Treg cell numbers were also increased (Pϭ0.0057; Figure 1C ). Fourteen days after commencing the treatment, Tregs remained elevated (Pϭ0.0002, Pϭ0.0043, and Pϭ0.0056 in the spleen, the liver, and the inguinal lymph nodes, respectively), although those in the liver were reduced in number compared with day 7 ( Figure 1A through 1C ). Because IL-2 is essential for Tregs homeostasis, playing a role in their maintenance and peripheral expansion, 20 we examined whether sustained elevated levels of IL-2 in plasma could contribute to the increase in Tregs. Administration of IL-2 alone (5 g) resulted in plasma concentrations of 171Ϯ58 and 16Ϯ9 pg/mL (nϭ3) 6 and 24 hours latter; in contrast, the same dose of IL-2 complexed with the antibody resulted in plasma concentrations in excess of 1000 pg/mL (nϭ3), both 6 and 24 hours later (PϽ0.0001; ie, up to 60-fold increases compared with IL-2 alone). Consequently we used the IL-2/anti-IL-2 mAb protocol to increase and maintain elevated Tregs numbers during the course of our atherosclerosis studies, administering doses of IL-2/anti-IL-2 mAb complex 3 times weekly (see below). To determine whether the IL-2/anti-IL-2 mAb treatment altered the phenotypic characteristics of the Tregs we compared the proportion of Tregs that expressed lymphocyte-activating gene-3 (LAG-3), inducible costimulator (ICOS), and L-selection (CD62L). LAG-3 is a CD4-related molecule that binds major histocompatibility complex class II, is expressed on activated Tregs, 21 and 
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contributes to suppression. 21 ICOS is a T cell receptor-inducible receptor that enhances T cell responses; ICOSϩ Tregs use interleukin-10 to suppress dendritic cell function and TGF-␤ to suppress T cell function, whereas ICOS-Tregs use only TGF-␤. 9, 22 CD62L is an important T-cell homing receptor. 23 The expression of LAG-3, ICOS, and CD62L was unaltered on the IL-2/anti-IL-2 mAb complex expanded Tregs population (PϾ0.05; Figure 1D ). Tregs expanded using the IL-2/anti-IL-2 mAb complex effectively attenuated CD4ϩ T cell proliferation in vitro ( Figure 1E ).
IL-2/Anti-IL-2 mAb Complexes Initiate Sustained Selective Expansion of Tregs and Increase Tregs in Atherosclerotic Lesions
After 6 weeks of IL-2/anti-IL-2 mAb complex therapy, Tregs were selectively elevated 2.2-fold in the spleen (Pϭ0.0001; Figure 2A ), whereas CD4ϩ T cells, CD8ϩ T cells, and NK cell numbers were unaffected (PϾ0.05; Figure 2B ). Tregs were also elevated in the liver (0.67Ϯ0.15ϫ10 5 Figure 2C ).
IL-2/Anti-IL-2 mAb Therapy Inhibits Atherosclerotic Plaque Development and Reduces Plaque Inflammatory Cells
To determine whether cytokine therapy with IL-2/anti-IL-2 mAb complexes attenuates atherosclerosis, we treated 6-weekold ApoE Ϫ/Ϫ mice with IL-2/anti-IL-2 mAb complexes while they were fed a high-fat diet for 8 weeks, commencing treatment 2 weeks after starting the high-fat diet. No adverse effects frequently associated with high dose IL-2 treatment were observed and body weights and plasma lipid profiles were unaffected (Table) ; plasma aspartate aminotransferase and alanine transaminase were also unaffected (not shown). Mice treated with the IL-2/anti-IL-2 mAb complex exhibited Ϸ50% reduction in aortic sinus atherosclerotic lesion size compared with control mice (mean aortic sinus plaque area 88 889Ϯ10 755 m 2 versus 172 375Ϯ16 410 m 2 in IL-2/ anti-IL-2 mAb complex-treated mice and control mice, respectively, Pϭ0.0060; Figure 3A ). To confirm that this was a result of the IL-2/anti-IL-2 mAb complex rather than the anti-IL-2 mAb, the same dose of anti-IL-2 mAb without IL-2 was administered; an additional control group received vehicle.
In the anti-IL-2 mAb-treated mice lesion size was similar to control, averaging 158 950Ϯ19 200 mm 2 (anti-IL-2 mAb group) and 169 800Ϯ20 400 mm 2 in the control group (nϭ6; PϾ0.05). To determine whether treatment affected immune cells in the lesions, we performed immunohistochemistry. IL-2/anti-IL-2 mAb complex treatment reduced CD4ϩ T cell numbers by 73% (Pϭ0.0108; Figure 3C ), macrophage accumulation by 65% (Pϭ0.0061; Figure 3B ), and cell proliferation (proliferating cell nuclear antigen) by 30% (Pϭ0.0320; Figure 3D ). CD83, a marker of mature dendritic cells, which is required for T cell activation, 24 was reduced by 67% (Pϭ0.0473; Figure 3E ); mRNAs encoding CD4, proliferating cell nuclear antigen, and CD83 was also markedly reduced (Pϭ0.0489, Pϭ0.0482, and Pϭ0.0495, respectively; Figure 4B ).
Expression of Inflammatory Markers in Atherosclerotic Lesions
To determine the mechanisms by which IL-2/anti-IL-2 mAb complex reduced lesion development, we examined effects on markers of inflammation. Expression of monocyte chemoattractant protein-1 (MCP-1) was markedly reduced in lesions of IL-2/anti-IL-2 mAb complex-treated mice (Pϭ0.0028; Figure  4A ); vascular cell adhesion molecule-1 (VCAM-1) was also reduced by Ϸ65% (Pϭ0.0008; Figure 4A ). mRNA encoding MCP-1 and VCAM-1 were also reduced, by 75% (Pϭ0.0410) and 72% (Pϭ0.0081), respectively ( Figure 4B ). TGF-␤1 mRNA tended to increase but was not significant (PϾ0.05; not shown).
IL-2/Anti-IL-2 mAb Complexes Attenuate Splenocyte Proliferation and Cytokine Secretion
To determine whether induction of Tregs by IL-2/anti-IL-2 mAb complex treatment affected the proliferative ability of splenocytes, we examined their proliferation in response to anti-CD3 antibodies. After 3 days culture with anti-CD3 antibodies, the proliferation of splenocytes from the IL-2/ anti-IL-2 mAb complex-treated mice was attenuated by up to 35% compared with control mice (Pϭ0.0100, Pϭ0.0010, and Pϭ0.0010 for 0.25 g, 0.5 g, and 1.0 g anti-CD3 antibodies used, respectively; Figure 5A ). Body weights, g 30Ϯ0.5 (10) 29Ϯ1.0 (10) 31Ϯ1.0 (14) 31Ϯ1 (12) The number of mice in each group is indicated by n. HFD indicates high-fat diet; IL, interleukin; mAb, monoclonal antibody; VLDL/LDL, very low-density/low-density lipoprotein; and HDL, high-density lipoprotein.
Table. Plasma Lipid Profiles and Body Weights of Control and IL-2-mAb-Treated Mice After 8 Weeks (Development Study) or 12 Weeks (Progression Study) on a High-Fat Diet
To determine whether secretion of cytokines was also affected, splenocytes isolated from the IL-2/anti-IL-2 mAbtreated and control mice were stimulated with anti-CD3 antibodies and cytokines in the medium measured. Stimulated splenocytes from IL-2/ anti-IL-2 mAb complex-treated mice secreted markedly lower amounts of Th1, Th2, and Th17 cell-derived cytokines compared with splenocytes from control mice. IL-1␤ was reduced by Ͼ90%, IL-4 by 50%, IL-10 by 70%, IL-13 by 80%, IL-17 by 55%, interferon-␥ by 85%, and tumor necrosis factor-␣ by 90% ( Figure 5B and Figure I in the online-only Data Supplement); cell viability was similar, averaging 80%.
IL-2/Anti-IL-2 mAb Complex Therapy Attenuates Progression of Developed Atherosclerosis
Previous studies using anti-CD3 antibodies to elevate CD4ϩLAPϩ Tregs suppressed only development of atheroscle-rosis. 14 To determine whether the IL-2 antibody treatment suppressed already developed atherosclerosis, 6-week-old ApoE Ϫ/Ϫ mice were fed a high-fat diet for 6 weeks after which they were treated with the IL-2/anti-IL-2 mAb complex for the ensuing 6 weeks while continuing the high-fat diet. The treatment markedly attenuated further progression of atherosclerosis, by 67% when compared with lesion size at the commencement of treatment (Pϭ0.0015; Figure 6A ). Immunohistochemical comparison of lesions showed marked reductions in macrophage accumulation (Pϭ0.0064), CD4ϩ T cell numbers (Pϭ0.0189), CD83ϩ dendritic cells (Pϭ0.0213), proliferating cell nuclear antigenϩ proliferating cells (Pϭ0.0157), as well as VCAM-1 (Pϭ0.0001) and MCP-1 expression (Pϭ0.0260) ( Figure II in the online-only Data Supplement). These reductions were associated with a doubling in Tregs in the spleen (Pϭ0.0001; Figure 6B ) and no changes in CD4ϩ, CD8ϩ T cells, or NK cells (PϾ0.05; Figure 6C and 6D). 
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Discussion
Recent studies have provided evidence of a protective role for Tregs in the development of atherosclerosis. 14, 15 Adoptively transferred naturally occurring Tregs, defined by high expression of CD25 on their surface and the transcription factor forkhead box P3 (Foxp3), attenuate development of atherosclerosis. 7 However, adoptive transfer therapy using Tregs is limited by inadequate purity of isolated Tregs cell population, insufficient numbers for transfer, and the potential instability of these cells. 11 In this study we demonstrate an alternative to adoptive transfer by selective in vivo expansion of Tregs numbers that are normally present in low numbers in atherosclerotic lesions. 6 Low doses of IL-2 complexed with an anti-IL-2 neutralizing antibody (JES6 -1) induced a sustained increase in systemic and lesional Tregs, which attenuates not only development of atherosclerosis but also progression of developed atherosclerosis. Our data demonstrate that lowdose IL-2 cytokine/anti-IL-2 neutralizing mAb complex therapy can be used to attenuate both progression and development of atherosclerosis, by selectively expanding in vivo the natural Treg population; the action of the IL-2/anti-IL-2 mAb complex is essential as anti-IL-2 mAb alone has no effect on lesion development. IL-2 plays a critical role in regulating the homeostasis of Tregs. 25 To selectively expand Tregs, we took advantage of IL-2/anti-IL-2 mAb immune complexes initially described by Boyman et al 26 and modified the dose regimen to induce sustained increases in Tregs numbers during hyperlipidemia for treating atherosclerosis. Although the dose regimen is highly effective in elevating Tregs numbers, the mechanisms by which IL-2/anti-IL-2 mAb complexes stimulate expansion of Tregs are yet to be fully defined. Complexing IL-2 with anti-IL-2 neutralizing mAbs prolongs the half-life of IL-2 in plasma, reducing the necessity for high-dose IL-2 treatment 17 ; the lifespan of IL-2/anti-IL-2 mAb complexes is Ϸ72 hours. 27 We also observed markedly elevated levels of IL-2 after complexing IL-2 with the IL-2 neutralizing antibody JES6 -1. IL-2/anti-IL-2 (JES6 -1) mAb complexes bind selectively to the relatively small population of CD25-expressing cells, mostly CD4ϩCD25ϩ T cells with activity highly dependent on the neonatal IgG receptor FcRn. 27 IL2/anti-IL2 mAb interaction with Tregs is highly dependent on this mAb because complexing IL-2 with another mAb, S4B6, stimulates expansion of NK and CD8 T cells. 19 In our study IL-2/anti-IL-2 (JES6 -1) mAb complexes selectively increased Tregs numbers in spleens, lymph nodes, and atherosclerotic lesions of hyperlipidemic mice without affecting CD4ϩ, CD8ϩ T cells, or NK cells. Also, the pattern of Lag-3, ICOS, and CD62L expression by Tregs was unaltered by IL-2 mAb complex treatment.
The sustained selective expansion of Tregs in lymphoid compartments and their increased numbers in atherosclerotic lesions after treatment with IL-2/anti-IL-2 mAb complexes suppressed atherosclerosis development and exerted multiple effects on immune cells within developing lesions. CD4ϩ T cells are a population with demonstrated proatherogenic activity, 4 and reductions in CD4ϩ T cells are associated with reductions in lesion size. 28 We found reduced CD4ϩ T cells in lesions. This is likely a result of local inhibition of CD4ϩ T cell proliferation by the increased Tregs within atherosclerotic lesions This is supported by our observation of reduced numbers of proliferating cell nuclear antigen-expressing proliferating cells in lesions, by reduced splenocyte proliferation, and dose-dependent inhibition of CD4ϩ T cell proliferation in vitro by the expanded Treg population. Expansion of Tregs in lymphoid compartments including lymph nodes also raises the possibility of concomitant suppression of atherogenic CD4 T cells in lymph nodes. Although our study focused on CD4 T cells, it is possible that the expanded Treg population also inhibited other proatherogenic T cells, namely CD8ϩ T cells and NKT cells, which also accumulate in lesions and are inhibited by Tregs. 29, 30 These cells also contribute to the splenocyte population whose proliferation was attenuated in mice treated with IL-2/anti-IL-2 (JES6 -1) mAb.
Both CD4ϩ Th1-and Th2-derived cytokines, including interferon-␥, IL-12, and IL-4, contribute to development of atherosclerosis, 31, 32 In this study IL-2/anti-IL-2 mAb complex therapy effectively prevented their secretion in stimulated splenocytes, indicating that the Tregs expanded by IL-2/anti-IL-2 mAb complex, like naturally occurring Tregs, suppress the ability of CD4ϩ Th1, Th2, and Th17 cells to secrete cytokines. 33 Our finding that splenocytes from control mice express significant quantities of Th2 cytokines-IL-4, IL-10, and IL-13 as well as the Th1 cytokine interferon-␥ is consistent with studies indicating that a high-fat diet initiates Th1 and Th2 responses in hyperlipidemic mice. 34 At present it is unclear as to the mechanisms used by the expanded Tregs to inhibit T cell responses and atherosclerosis. Given that a number of different subtypes of Tregs are present, including LAG-3, CD62L, and ICOS ϩve and -ve Tregs, it is likely that a number of mechanisms are involved. ICOSϩ Tregs use IL-10 to suppress dendritic cell function and TGF-␤ to suppress T cell function whereas ICOS-Tregs use predominantly IL-10. 9 Tregs can also use cytokines or enzymes expressed on their cell surface to inhibit immune responses. Contact-dependent inhibition by Tregs is dependent on cell surface expression of TGF-␤or galactin-1, 35 whereas their ability to generate the immunosuppressive agent adenosine is dependent on cell surface expression of CD39 and CD73. 36 Tregs may also attenuate CD4ϩ T cell activation by secreting phospholipase A2-IID. 37 Because we dosed the mice with IL-2/anti-IL-2 mAb complexes, it is unlikely that inhibition is the consequence of Tregs depriving other immune cells of IL-2. 38 In addition to suppressive effects on CD4 T cells, macrophage accumulation in lesions was also reduced in developing lesions. This is associated with similar reductions in expression of MCP-1 and VCAM-1, which very likely contribute to the reduction in macrophage accumulation. MCP-1 is produced by both macrophages and vascular smooth muscle cells, is chemotactic for monocytes/macrophages, and preventing its expression attenuates atherosclerosis. 39 Similarly, VCAM-1 contributes to macrophage accumulation. The reduction in VCAM-1 expression is most likely the consequence of Tregs attenuating both macrophage and CD4ϩ T cell activation; inhibiting CD4ϩ T cell activation by Tregs reduces IL-1␤ expression, a powerful inducer of VCAM-1 expression in lesions. Our finding of reductions in expression of CD83 suggests that IL-2-mAb treatment also attenuates maturation of dendritic cells. Tregs are known to inhibit dendritic cell maturation and can modulate dendritic cell phenotype, reducing expression of CD83. 40 As dendritic cells have a key role as antigen-presenting cells in initiating immunogenic CD4 T cell responses, their reduction may contribute to the suppression of atherogenic CD4 T cells.
Our data clearly demonstrate that IL-2/anti-IL-2 mAb complex treatment inhibits both atherosclerosis development and also progression of developed atherosclerotic lesions. Our studies also indicate that the expanded Tregs effectively target CD4ϩ T cells, macrophages, and dendritic cells in lesions to attenuate atherosclerosis. As only small numbers of Foxp3-expressing Tregs are present in human atherosclerotic lesions, 6 this approach of administering IL-2 complexed with an IL-2 neutralizing antibody that selectively targets Tregs expansion could be a promising therapeutic approach for attenuating immunoinflammation and progression of preexisting atherosclerotic vascular disorders. Recently, neutralizing the chemokine CCL17 has also been shown to increase Treg numbers and attenuate development of atherosclerosis. 41 However, unlike IL-2/anti-IL-2 mAb treatment, which expands natural Tregs, 18 neutralizing CCL17 appears to accelerate the conversion of CD4ϩCD25-T cells to inducible Tregs in the periphery, their proliferation, and also the proliferation of CD4ϩCD25-T cells. Furthermore, in vitro 
